Actualités Algernon Pharmaceuticals Inc - AGN | Actions Canadian Securities Exchange

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

VANCOUVER, British Columbia, Feb. 10, 2021 -- InvestorsHub NewsWire -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW...

Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for ...

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN...

Algernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for...

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory...

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency...

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus VANCOUVER, British Columbia, Canada -- March 6, 2020...

Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) ...

Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent...

Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis ...

Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in...

Algernon Pharmaceuticals' NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56%

Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis...

Q&A with Christopher J. Moreau CEO of Algernon Pharmaceuticals

#outlook a {padding:0;} body {width:100%; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; margin:0; padding:0;} .ReadMsgBody...

Algernon Pharmaceuticals: Join us for an interview with the CEO and CSO

p{margin:10px 0;padding:0;}table{border-collapse:collapse;}h1,h2,h3,h4,h5,h6{display:block;margin:0;padding:0;}img,a...

Repurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBD

Repurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBD Time to put down your...

BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educatio

MADISON HEIGHTS, Mich., Dec. 4 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today...

Critical Alerts for Apple, Alcoa, CarMax, Allergan, and AnnTaylor Released by Seven Summits Research

CHICAGO, Sept. 29 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for AAPL, AA, KMX, AGN, and ANN. Seven Summits Strategic...

Video: Allergan Announces the LATISSE(TM) Wishes Campaign, Committing $1 Million to The Make-A-Wish Foundation(R)

Register on LATISSE(TM) Web Site to Help Reach Goal IRVINE, Calif., March 27 /PRNewswire-FirstCall/ -- Allergan, Inc. (NYSE: AGN) hosted a...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Algernon Pharmaceuticals Inc (AGN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

AGN Actualités

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for ...

Algernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) ...

Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis ...

Algernon Pharmaceuticals' NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56%

Q&A with Christopher J. Moreau CEO of Algernon Pharmaceuticals

Algernon Pharmaceuticals: Join us for an interview with the CEO and CSO

Repurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBD

BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educatio

Critical Alerts for Apple, Alcoa, CarMax, Allergan, and AnnTaylor Released by Seven Summits Research

Video: Allergan Announces the LATISSE(TM) Wishes Campaign, Committing $1 Million to The Make-A-Wish Foundation(R)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Algernon Pharmaceuticals Inc (AGN) Actualités

Algernon Pharmaceuticals Inc (AGN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

AGN Actualités

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for ...

Algernon Receives U.S. FDA Clearance for Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard

Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency

Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus

Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) ...

Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis ...

Algernon Pharmaceuticals' NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56%

Q&A with Christopher J. Moreau CEO of Algernon Pharmaceuticals

Algernon Pharmaceuticals: Join us for an interview with the CEO and CSO

Repurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBD

BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educatio

Critical Alerts for Apple, Alcoa, CarMax, Allergan, and AnnTaylor Released by Seven Summits Research

Video: Allergan Announces the LATISSE(TM) Wishes Campaign, Committing $1 Million to The Make-A-Wish Foundation(R)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités